MARY HALBROOKS: Open Payments
NPI 1780151514 · HARTSELLE, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$856 in 46 payments from 14 companies in 2025. Trend: 2023 $631 · 2024 $662 · 2025 $856
Food & beverage: $856
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 10 | $197 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $122 |
| AstraZeneca Pharmaceuticals LP | 6 | $114 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 6 | $94 |
| Lilly USA, LLC | 4 | $76 |
| Astellas Pharma US Inc | 2 | $43 |
| Exact Sciences Corporation | 2 | $41 |
| Dexcom, Inc. | 2 | $35 |
| Otsuka America Pharmaceutical, Inc. | 2 | $28 |
| GlaxoSmithKline, LLC. | 1 | $26 |
Products named: CAPLYTA, Ozempic, JARDIANCE, BREZTRI, MOUNJARO, Veozah, FARXIGA, Rybelsus.
Industry payments across AL — which companies pay providers there.
